𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pravastatin treatment in combined hyperlipidaemia

✍ Scribed by S. Zambon; A. Cortella; G. Sartore; G. Baldo-Enzi; E. Manzato; G. Crepaldi

Publisher
Springer
Year
1994
Tongue
English
Weight
363 KB
Volume
46
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

✦ Synopsis

Combined hyperlipidaemia and the presence of small and dense LDL particles in the circulation are associated with an increased risk of myocardial infarction.

The effect of pravastatin on plasma lipoproteins and on LDL size has been evaluated in a single-blind, randomised, placebo-controlled study in 24 patients with combined hyperlipidaemia; 12 patients on pravastatin and 12 on placebo.

After 16 weeks on pravastatin, plasma total (-15 %) and LDL ( -23 %) cholesterol and apo B ( -13 %) levels were significantly reduced and apo AI (+ 6 %) had increased. LDL size (measured by gradient gel electrophoresis) had not changed. No adverse effect was observed.

The study suggests that, in combined hyperlipidaemia, LDL size is not affected by variation in LDL receptor activity.

πŸ“œ SIMILAR VOLUMES

Lipoprotein lipase activity in patients
Lipoprotein lipase activity in patients with combined hyperlipidaemia
✍ M. Seed; F. Mailly; D. Vallance; E. Doherty; A. Winder; P. Talmud; S. E. Humphri πŸ“‚ Article πŸ“… 1994 πŸ› Springer 🌐 English βš– 697 KB

The aetiology of familial combined hyperlipidaemia remains obscure, with both genetic and environmental factors contributing to the phenotype, which is frequently associated with premature coronary heart disease. We have studied lipoprotein lipase (LPL) activity and hepatic lipase (HL) activity in p